Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
Status:
Terminated
Trial end date:
2021-03-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of the drug ruxolitinib in
people diagnosed with COVID-19 pneumonia by determining the number of people whose conditions
worsen (requiring machines to help with breathing or needing supplemental oxygen) while
receiving the drug.
This is a sub-study of the U-DEPLOY study: UHN Umbrella Trial Defining Coordinated Approach
to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery. U-DEPLOY helps
to facilitate timely conduct of studies across the University Health Network and other
centers.